Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand
Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity and diabetes drugs.
Eli Lilly Cuts Q4 Revenue Guidance, Expects Around $5.5 Billion Sales From Weight Loss/Diabetes Drugs, Stock Tanks
Eli Lilly and Co (NYSE: LLY) announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 billion, representing a 32% growth compared to the previous year versus the consensus of $45.
Eli Lilly Buys Cancer Therapy And Announces Timing Of Weight Loss Pill
Pharmaceutical giant Eli Lilly & Co. (LLY) is buying privately held Scorpion Therapeutics’ experimental cancer therapy for $2.5 billion U.S. in cash. Eli Lilly is purchasing Scorpion’s experimental oral therapy called “STX-478,
Lilly forecasts weak fourth-quarter sales of weight-loss drug, shares slump
Eli Lilly forecast sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to miss Wall Street estimates in the fourth quarter, sending the drugmaker's shares down more than 8% on Tuesday.
Eli Lilly’s stock falls as weight-loss drug sales disappoint
Shares of Eli Lilly and Co. slipped 0.4% in premarket trading Tuesday, after the drug maker provided a disappointing fourth-quarter revenue outlook, citing slower-than-expected growth in sales of its weight-loss drugs.
Eli Lilly CEO tells Bloomberg TV company sees weight loss pill approval in 2026
Eli Lilly (LLY) expects that its experimental weight loss pill will get approved as soon as early next year, CEO David Ricks said in an
Eli Lilly CEO expects new weight loss pill to be approved next year
Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which dominate the weight loss drug market.
Eli Lilly CEO on Fighting Cancer and Obesity, Drug Pricing
Eli Lilly & Co. Chief Executive Officer Dave Ricks talks about paying $2.5 billion for a cancer drug being developed by Scorpion Therapeutics. He also says Lilly's experimental weight-loss pill could be approved in early 2026.
Hosted on MSN1h
Lilly forecasts weak sales of weight-loss drug in fourth quarter
(Reuters) - Eli Lilly expects sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to ...
radaronline1h
Dark Secrets of Ozempic Exposed: What Big Pharma Is Hiding About 'Miracle' Weight Loss Drug Loved by Celebs
Big Pharma is hiding a massive secret about so-called miracle weight-loss drugs like Ozempic – they come with a raft of ...
FDA Approves Weight-loss Drug Zepbound For Sleep Apnea – Will Insurance Cover This $1000-Per-Month Medication?
Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...
FierceBiotech1d
Kailera reports Zepbound-rivaling weight loss in phase 2 obesity trial
Fresh from a $400 million series A round, Kailera Therapeutics has shown off phase 2 data on an obesity candidate it believes ...
BioSpace2h
Pfizer Cautiously Optimistic on Obesity Pill as Kailera Challenges Lilly’s Zepbound With Strong Phase II Data
Obesity continues to grab attention at the JP Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera ...
Medicine Buffalo20h
UB pharmacy professor discusses pros and cons of popular weight-loss drugs
Nicole Albanese, PharmD, discusses the science behind weight-loss drugs, their potential to treat other addictions as well as ...
Morningstar8h
Mounjaro and Zepbound sales disappoint, and Eli Lilly's stock is dropping
The expected revenue total includes $3.5 billion in sales of diabetes treatment Mounjaro, which is below the FactSet consensus of $4.4 billion, and $1.9 billion in sales of weight-loss drug ...
Wegovy to Zepbound: The Pros and Cons of Weight Loss Medications
In a recent episode of the global health and wellness show Bloom, host Gayle Guyardo welcomed Dr. Bharti Shetye, MD, MFOMA, a ...